Why then would Theravance Biopharma make the comparisons of their TD-1473 UC candidate with Xeijanx (tofacitnib) relative to upper/lower intestinal tissue concentration in an SEC document?
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links